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Abstract 
Eukaryotic elongation factor 2 kinase (eEF-2K) (also 
known as Calmodulin (CaM)-dependent elongation 
factor 2 kinase,CaMKIII) is an unusual 
calcium/calmodulin (Ca2+/CaM)-dependent 
Threonin kinase that controls the rate of the 
elongation phase of protein synthesis through 
phosphorylating elongation factor 2 (eEF2)  (Nairn 
et al., 1985; Ryazanov 1987; Mitsui et al., 1993; 
Redpath et al., 1993). Phosphorylation of eEF2 on 
Thr-56  disrupts the interaction between eEF-2 and 
the ribosome, leading to reduced protein synthesis. 
eEF-2K is regulated  by phosphorylation by multiple 
signaling pathways and kinases at 11 different 
phosphorylation sides (Ryazanov et al., 1988; 
Carlberg et al., 1990; Abramczyk et al., 2011; 
Browne et al., 2004; Marshall et al., 2012; 
Chafouleas et al., 1981; Bowden et al.,  2013). 
Hypoxia, nutrient deprivation and metabolic stress 
are all known to stimulate eEF-2K through 
activation of AMPK (Chafouleas et al., 1981).The 
activity of eEF-2K is increased in rapidly 
proliferating malignant cells and in cancer 
specimens, but is absent in normal adjacent tissues 
(Ashour et al., 2014b). eEF-2K promotes cell 
proliferation, invasion and tumorigenesis of some 
cancers. eEF-2K expression (mRNA) correlates with 
poor patient survival and prognosis (outcome)  in 
some solid tumors, including breast , pancreatic 
cancer  and glioblastoma (Meric-Bernstam et al., 
2012). The activity of this kinase is increased in 
many cancers and may be a potential therapeutic 
target in some cancers. 
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Identity 
Other names: CaMK-III, eEF-2K, HSU93850 
HGNC (Hugo): EEF2K 
Location: 16p12.2 
DNA/RNA 
Note 
EEF2K gene encodes a Ca2+/calmodulin-dependent 
kinase known as eukaryotic elongation factor-2 
kinase (EEF2K). 
Description 
The EEF2K gene is composed of 18 exons. It spans 
approximately 80.35 kb of genomic DNA. 
Transcription 
This gene encodes 5 transcripts and protein coding 
transcript (EEF2K-001) has 7388 bp length and this 
is composed of 725 aa residues. EEF2K-002 is a non 
sense mediated decay. Other three transcripts 
(EEF2K-003, -004, -005) do not give rise to proteins. 
Pseudogene 
No pseudogene reported. 
Protein 
Description 
Human eukaryotic elongation factor-2 kinase is 
composed of 725 amino acids (105 KDa) alfa-kinase 
catalytic domain of this protein is located at the 
section of 76-356. Calmoduline (CaM) binding 
domain is located close to N-terminal and next to the 
catalytic domain. The function of the region located 
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N-terminal of the CaM-binding site is not well 
understood but removal of this segment leads to 
intrinsic autophosphorylation and activity; cause 
inhibitory effect on the EF2K activity. Contain 18 
phosphorylation sites. Autophosphorylated at 
multiple residues, Thr-348 is the major site. Towards 
the C-terminal region, there are four predicted alfa-
helical regions, and these resemble SEL-1-type 
repeats. The region lies between SEL-1 type repeats 
and the C-terminus contains higly reserved 
sequences. The extreme C terminus is known to be 
essential for the phosphorylation of eukaryotic 
elongation factor-2 (eEF2).  
Expression 
Ubiquitosly expressed in nomal tissues. Activity is 
increased in some tumors. 
Localisation 
Cytoplasmic. 
Function 
EEF2K protein belongs to alfa-kinases family of 
protein kinases. Its activity is dependent to 
Ca2+/calmodulin kinase and phosphorilates 
eukaryotic elongation factor-2 (eEF2) at Thr56 and 
inhibits it association/binding with ribosomes, thus 
regulates the elongation phase of translation. 
Mutations 
No mutations identified other than SNPs 
repsesenting normal variations 
(http://www.hgmd.cf.ac.uk/ac/gene.php?gene=EEF
2K) 
Implicated in 
Breast Cancer 
Note 
eEF-2K protein expression promotes in breast cancer 
cell survival, invasion, migration and tumorigenesis 
(Tekedereli et al., 2012). eEF-2k  highly expressed 
lines compared with normal non-tumorigenic breast 
epithelium and ist expression is associated with poor 
patient survival and prognosis (Meric-Bernstam et 
al., 2012). 
Prognosis 
Overexpression of eEF-2k is associated with shorter 
survival and poor prognosis (outcome) in Estrogen 
receptor (ER) positive (Tekedereli et al., 2012) and 
triple negative or ER (-) breast cancer patients 
(Ozpolat et al in press). 
Pancreatic cancer 
Note 
eEF-2K protein is significantly overexpressed in 
pancreatic cancer cell lines and its inhibition lead to 
inhibition of cell proliferation, in invasion and 
migration and induces apoptosis (Ashour et al., 
2014a; Ashour et al., 2014b). 
Glioblastome multiforme (GBM) 
Note 
eEF-2K protects cells from nutrient deprivation and 
in conferring tumor cell adaptation to nutrient 
deprivation and metabolic stress   by blocking 
translation elongation (Bowden et al.,  2013). 
Azheimer' disease (AD) 
Note 
Levels of p-eEF2K were found to be  significantly 
increased, and total eEF2 significantly decreased in 
AD, when compared to controls in the brain tissue. 
levels of p-MTOR (Ser2481), and EIF4EBP1 (p-4E-
BP1) (Thr70 and Ser65) dramatically increase in 
AD, and are positively significantly correlated with 
total tau and p-tau proteins. 
Hypertension 
Note 
eEF2K protein increases in mesenteric artery from 
spontaneously hypertensive rats (SHR). eEF2K 
mediates TNF-a-induced vascular inflammation via 
ROS-dependent mechanism, which is at least partly 
responsible for the development of hypertension in 
SHR (Usui et al., 2013). 
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